Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Update

Marker Therapeutics, Inc. (NASDAQ:MRKR) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 372,500 shares, a growth of 170.1% from the February 28th total of 137,900 shares. Based on an average daily trading volume, of 128,900 shares, the short-interest ratio is presently 2.9 days. Currently, 5.0% of the company’s shares are short sold.

Hedge Funds Weigh In On Marker Therapeutics

Several large investors have recently modified their holdings of MRKR. Alyeska Investment Group L.P. acquired a new stake in shares of Marker Therapeutics during the 4th quarter worth about $2,847,000. NEA Management Company LLC raised its stake in shares of Marker Therapeutics by 51.7% in the 4th quarter. NEA Management Company LLC now owns 1,625,678 shares of the company’s stock valued at $5,056,000 after acquiring an additional 554,250 shares during the period. Blue Owl Capital Holdings LP purchased a new stake in shares of Marker Therapeutics in the 4th quarter valued at approximately $1,724,000. LPL Financial LLC purchased a new position in shares of Marker Therapeutics during the 4th quarter worth approximately $248,000. Finally, Northern Trust Corp increased its holdings in Marker Therapeutics by 66.9% in the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock valued at $168,000 after purchasing an additional 21,703 shares during the last quarter. Institutional investors and hedge funds own 22.39% of the company’s stock.

Marker Therapeutics Stock Down 7.3 %

Shares of MRKR stock traded down $0.10 during trading on Friday, hitting $1.27. 38,420 shares of the stock traded hands, compared to its average volume of 58,693. Marker Therapeutics has a 52-week low of $1.13 and a 52-week high of $5.99. The firm’s fifty day moving average price is $1.63 and its 200-day moving average price is $2.73.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MRKR. Brookline Capital Management upgraded Marker Therapeutics to a “strong-buy” rating in a report on Monday, February 10th. Canaccord Genuity Group began coverage on shares of Marker Therapeutics in a report on Wednesday, March 5th. They issued a “buy” rating and a $8.00 price objective for the company.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.